Association of the VEGF 936C>T polymorphism with FDG uptake, clinical, histopathological, and metabolic response in patients with adenocarcinomas of the esophagogastric junction.
OBJECTIVE
The MUNICON trial confirmed prospectively the usefulness of early response evaluation by 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography (FDG-PET) . Metabolic responders (R) showed initially a higher FDG uptake compared with nonresponders (p = 0.018). An association of the vascular endothelial growth factor (VEGF) 936C>T polymorphism and FDG uptake was reported for breast cancer. Therefore, we investigated the VEGF 936C>T polymorphism for an association with response and survival.


METHODS
The study was based on 110 patients included in the MUNCON trial (103 male, seven female; 75 AEG I, 35 AEG II, event-free survival (EFS) median 21.1 ± 4.6 months). Response was significantly associated with EFS. The VEGF 936C>T polymorphism was determined by PCR and restriction fragment length polymorphism analysis. For analysis, the T-variants were combined.


RESULTS
One hundred two patients were evaluable. Seventy-two patients showed the CC, 24 the CT, and six the TT genotype. Median EFS was 29.3 months for CC and 11.7 months for CT/TT (p = 0.04). No association of the genotypes (CC or CT/TT) with the SUV or response was found. Multivariate analysis revealed histopathological regression (p = 0.003) and genotype (p = 0.04) as independent prognostic factors. A combination of genotype and PET response (Gen-PET) defines three prognostic groups early in the course of treatment (p = 0.002). Cox regression analysis including clinical and histopathological response and Gen-PET reveals Gen-PET as independent prognostic factor (p = 0.003).


CONCLUSIONS
The VEGF 936C>T polymorphism is a prognostic factor in patients undergoing neoadjuvant chemotherapy, although it is not associated with FDG uptake and response. The combination of metabolic response and VEGF 936C>T polymorphism defines three different prognostic groups. These findings need to be confirmed prospectively. This study has been registered in the European Clinical Trials Database as trial 2007-003356-11.
Lorenzen
Sylvie
S
National Center of Tumor Diseases, University of Heidelberg, Heidelberg, Germany.
Panzram
Ben
B
Keller
Gisela
G
Lordick
Florian
F
Herrmann
Ken
K
Becker
Karin
K
Langer
Ruppert
R
Schwaiger
Markus
M
Siewert
Jorg Rudiger
JR
Ott
Katja
K
D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001483:Base Sequence; D017931:DNA Primers; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism*; D006801:Humans; D011110:Polymorphism, Genetic; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*
D000970:Antineoplastic Agents; D017931:DNA Primers; D042461:Vascular Endothelial Growth Factor A; D019788:Fluorodeoxyglucose F18
Lancet Oncol. 2007 Sep;8(9):797-805
17693134
J Clin Oncol. 2001 Feb 15;19(4):1207-25
11181687
Clin Cancer Res. 2005 May 15;11(10):3647-53
15897560
Anticancer Res. 2008 Mar-Apr;28(2B):1271-6
18505065
Clin Cancer Res. 2007 Feb 1;13(3):898-901
17289883
Breast Cancer Res Treat. 2004 Dec;88(3):205-8
15609122
Cancer. 2000 Apr 15;88(8):1788-95
10760753
J Clin Oncol. 2000 Oct 15;18(20):3495-502
11032590
J Surg Oncol. 2006 Dec 1;94(7):624-30
17111394
J Clin Oncol. 2001 Jun 15;19(12):3058-65
11408502
J Cancer Res Clin Oncol. 2007 Oct;133(10):787-91
17564725
Proc Natl Acad Sci U S A. 2005 May 24;102(21):7677-82
15890779
Ann Surg. 1999 Mar;229(3):303-8
10077040
Cancer. 2003 Oct 1;98(7):1521-30
14508841
Cancer. 1996 Mar 1;77(5):858-63
8608475
Gynecol Oncol. 2003 Dec;91(3):513-7
14675669
Int J Cancer. 2003 Sep 10;106(4):468-71
12845639
Ann Oncol. 2007 Jun;18(6):1030-6
17426061
Ann Surg Oncol. 2009 Apr;16(4):1017-25
19189186
Clin Cancer Res. 2008 Nov 15;14(22):7554-63
19010874
Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):878-83
17195074
J Vasc Res. 2000 Nov-Dec;37(6):443-8
11146397
J Clin Oncol. 2005 Feb 10;23(5):1011-27
15585754
J Clin Oncol. 2002 Jan 15;20(2):379-87
11786564
Onkologie. 2008 Jul;31(7):366-72
18596383
Cancer Res. 2005 Jun 15;65(12):5015-9
15958542
J Clin Oncol. 2006 Apr 10;24(11):1720-8
16520463
J Nucl Med. 2005 Dec;46(12):2029-34
16330567
Gastric Cancer. 2003;6(3):159-67
14520529
Biochem Biophys Res Commun. 2004 Dec 3;325(1):144-50
15522212
Clin Cancer Res. 2008 Jan 1;14(1):62-6
18172253
Ann Surg. 2007 Oct;246(4):624-8; discussion 628-31
17893499
Radiology. 2005 Sep;236(3):841-51
16118165
J Clin Oncol. 2008 Feb 20;26(6):856-62
18281657
Ann Surg. 2002 Jul;236(1):37-42
12131083
J Clin Oncol. 2006 Apr 20;24(12):1883-91
16622263
Ann Oncol. 2008 Oct;19(10):1734-41
18550579
Eur J Cancer. 1996 Dec;32A(14):2501-5
9059339
Int J Cancer. 2006 Dec 15;119(12):2885-94
16929515
Br J Cancer. 2002 Nov 4;87(10):1057-65
12402142
J Clin Oncol. 2006 Nov 20;24(33):5201-6
17114652
J Clin Oncol. 2006 Oct 10;24(29):4692-8
16966684
Clin Cancer Res. 2009 Jul 15;15(14):4680-5
19584152